header image

R&D Recombinant

Octapharma's R&D Recombinant Group is dedicated to:


  • The development of therapeutic human recombinant products
  • Clinical upscale and pharmaceutical scale production


Recombinant proteins are produced in cultured human cells. Human recombinant proteins produced in human cell lines show identical properties to the same protein derived directly from human tissues and blood. They are therefore anticipated to show improved tolerance in patients compared to currently available hamster cell-derived recombinant products.


Octapharma’s first recombinant product, blood clotting Factor VIII (Human-cl rhFVIII), was approved by the Therapeutic Goods Administration in November 2014. The product is undergoing further assessment in research projects in different stages of development.


The R&D Recombinant Group comprises: